

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

**Dated July 29, 2016**

**Commission File Number 001-36421**

**AURINIA PHARMACEUTICALS INC.**

**(Exact name of Registrant as specified in its charter)**

**N/A**

**(Translation of Registrant's Name)**

**#1203-4464 Markham Street  
Victoria, British Columbia  
V8Z7X8**

**(250) 708-4272**

**(Address and telephone number of registrant's principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [  ] Form 40-F [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): [  ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): [  ]

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ] No [  ]

This Form 6-K is hereby filed and incorporated by reference in the registrant's Registration Statement on Form F-10 (File No. 333-206994).

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: July 29, 2016.

**Aurinia Pharmaceuticals Inc.**

By: /s/ Dennis Bourgeault

Name: Dennis Bourgeault

Title: Chief Financial Officer

## EXHIBIT INDEX

<b>Exhibit</b>	<b>Description of Exhibit</b>
<a href="#"><u>99.1</u></a>	<a href="#"><u>Material Change Report dated July 29, 2016</u></a>

Exhibit 99.1 included with this report on Form 6-K is hereby incorporated by reference as an exhibit to the Registration Statement on Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-206994), as amended or supplemented.

**FORM 51-102F3  
Material Change Report**

**Item 1 Name and Address of Company**

Aurinia Pharmaceuticals Inc. (the "Company")  
#1203-4464 Markham Street  
Victoria, BC A1 V8Z 7X8

**Item 2 Date of Material Change**

July 22, 2016

**Item 3 News Release**

A news release was issued and disseminated by the Company through Business Wire on July 22, 2016.

**Item 4 Summary of Material Change**

The Company announced that it has entered into a Controlled Equity Offering Sales Agreement (the "ATM Agreement") with Cantor Fitzgerald & Co. ("Cantor") pursuant to which the Company may from time to time sell, through at-the-market ("ATM") offerings with Cantor acting as sales agent, such common shares as would have an aggregate offer price of up to US\$10,000,000.

**Item 5 Full Description of Material Change**

The Company announced that it has entered into the ATM Agreement with Cantor pursuant to which the Company may from time to time sell, through an ATM offerings with Cantor acting as sales agent, such common shares as would have an aggregate offer price of up to US\$10,000,000. The offering will be made by way of a prospectus supplement dated July 22, 2016 and filed by the Company with securities regulatory authorities in Canada in the provinces of British Columbia, Alberta and Ontario, and with the United States Securities and Exchange Commission, which supplements the Company's short form base shelf prospectus dated October 16, 2015, and the Company's shelf registration statement on Form F-10 dated October 16, 2015, declared effective on November 5, 2015.

Cantor, at the Company's discretion and instruction, will use its commercially reasonable efforts to sell the common shares at market prices from time to time. Sales in the ATM Offering will only be conducted in the United States through NASDAQ or another exchange at market prices. No sales will be conducted in Canada or through the Toronto Stock Exchange.

The Company currently intends to use the proceeds from sales related to the ATM offering, if any, primarily for working capital and general corporate purposes, including to fund its lupus nephritis clinical trial program for voclosporin.

---

**Item 5.2 Disclosure of Restructuring Transactions**

Not applicable.

**Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7 Omitted Information**

No significant facts remain confidential in, and no information has been omitted from, this report.

**Item 8 Executive Officer**

For further information, please contact:

Mr. Michael R. Martin, Chief Operating Officer  
250-415-9713  
mmartin@auriniapharma.com

**Item 9 Date of Report**

July 29, 2016

***Cautionary Note Regarding Forward-looking Statements***

*This report contains forward-looking statements. Forward-looking statements in this report include statements about the possible sales of common shares and statements of the current intended use of proceeds from the sale of shares, if any. The forward-looking statements may include, without limitation, statements that the net proceeds from the sale of the common shares will be used primarily for working capital and general corporate purposes, including to fund the LN clinical trial program for voclosporin. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the ability of the Company to protect its intellectual property rights, securing and maintaining corporate alliances and partnerships, the need to raise additional capital and the effect of capital market conditions and other factors on capital availability, the potential of its products, the success and timely completion of clinical studies and trials, and the combined company's and its partners' ability to successfully obtain regulatory approvals and commercialize voclosporin on a timely basis. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. For additional information on risks and uncertainties relating to these forward-looking statements, investors should review the prospectus supplement and accompanying prospectus and consult the Company's ongoing quarterly filings, annual reports and the Annual Information Form and other filings found on SEDAR at [www.sedar.com](http://www.sedar.com) and on EDGAR at [www.sec.gov/edgar](http://www.sec.gov/edgar).*

---